July 2 (Reuters) - Mesoblast Ltd MSB.AX :
* ENTERS US$50 MILLION FINANCING WITH NOVAQUEST CAPITAL FOR REMESTEMCEL-L IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE
* NOVAQUEST WILL PROVIDE A NON-DILUTIVE US$40 MILLION, EIGHT-YEAR TERM LOAN AND PURCHASE US$10 MILLION OF MESOBLAST COMMON SHARES